Duplication, multiduplication, and amplification of genes encoding drug- metabolizing enzymes: Evolutionary, toxicological, and clinical pharmacological aspects

Drug Metabolism Reviews

Volumn 31, Issue 2, 1999, Pages 449-459

  Ingelman Sundberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alkaloids; CYP2D6; Debrisoquine; Ethiopians; GSTM7

Indexed keywords

ALKALOID; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; GLUTATHIONE TRANSFERASE;

CONFERENCE PAPER; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE DUPLICATION; GENE STRUCTURE; GENETIC ANALYSIS;

CYTOCHROME P-450 CYP2D6; EVOLUTION, MOLECULAR; GENE AMPLIFICATION; GENE DUPLICATION; GLUTATHIONE TRANSFERASE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY, CLINICAL; PHENOTYPE;

EID: 0032954826     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101930     Document Type: Conference Paper

References (27)

1. R. J. Bertz and G. R. Granneman, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions, Clin. Pharmacokinet., 32, 210-258 (1997).
2. L. Bertilsson, M. L. Dahl, F. Sjöqvist, A. Åberg-Wistedt, M. Humble, I. Johansson, E. Lundqvist, and M. Ingelman-Sundberg, Molecular basis for rational mega prescribing in ultrarapid hydroxylators of debrisoquine, Lancet, 341, 63 (1993).
3. I. Johansson, E. Lundqvist, L. Bertilsson, M. L. Dahl, F. Sjöqvist, and M. Ingelman-Sundberg, Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine, Proc. Natl. Acad. Sci. USA, 90, 11825-11829 (1993).
4. Q. Y. Yue, L. Bertilsson, M. L. Dahl-Puustinen, J. Säwe, F. Sjöqvist, I. Johansson, and M. Ingelman-Sundberg, Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese, Lancet, 2, 870 (1989).
5. I. Johansson, M. Oscarson, Q. Y. Yue, L. Bertilsson, F. Sjöqvist, and M. Ingelman-Sundberg, Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation, Mol. Pharmacol., 46, 452-459 (1994).
6. C. Mura, J. P. Broyard, E. Jacqz-Aigrain, and R. Krishnamoorthy, Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese. Br. J. Clin. Pharmacol., 32, 135-136 (1991).
7. L. Bertilsson, A. Åberg-Wistedt, L. L. Gustafsson, and C. Nordin, Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants, Ther. Drug. Monit., 7, 478-480 (1985).
8. M. H. Heim and U. A. Meyer, Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6, Genomics, 14, 49-58 (1992).
9. I. Roots, N. Drakoulis, and J. Brockmöller, Polymorphic enzymes and cancer risk: Concepts, methodology and data review, in Pharmacogenetics of Drug Metabolism (W. Kalow, ed.) Pergamon Press, Elmsford, NY, 1992, pp. 815-842.
10. E. Aklillu, I. Persson, L. Bertilsson, I. Johansson, F. Rodrigues, and M. Ingelman-Sundberg, Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles, J. Pharmacol. Exp. Ther., 278, 441-446 (1996).
11. R. A. McLellan, M. Oscarson, J. Seidegård, D. A. Evans, and M. Ingelman-Sundberg, Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians, Pharmacogenetics, 7, 187-191 (1997).
12. J. A. Agundez, M. C. Ledesma, J. M. Ladero, and J. Benitez, Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population, Clin. Pharmacol. Ther., 57, 265-269 (1995).
13. M. L. Dahl, I. Johansson, L. Bertilsson, M. Ingelman-Sundberg, and F. Sjöqvist, Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis, J. Pharmacol. Exp. Ther., 274, 516-520 (1995).
14. C. Sachse, J. Brockmöller, S. Bauer, and I. Roots, Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 60, 284-295 (1997).
15. J. A. Agundez, R. Ramirez, M. Hernandez, A. Llerena, and J. Benitez, Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: Impact of gene-flow from Europe, Pharmacogenetics, 7, 337-340 (1997).
16. L. Bathum, I. Johansson, M. Ingelman-Sundberg, M. Horder, and K. Broder, Ultrarapid metabolism of sparteine: Frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by RFLP and long PCR, Pharmacogenetics, 8, 119-123 (1998).
17. C. M. Masimirembwa, I. Johansson, J. A. Hasler, and M. Ingelman-Sundberg. Genetic polymorphism of cytochrome P450 CYP2D6 in a Zimbabwean population, Pharmacogenetics, 3, 275-280 (1993).
18. H.-K. Roh, M.-L. Dahl, I. Johansson, M. Ingelman-Sundberg, Y.-N. Cha, and L. Bertilsson, Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population, Pharmacogenetics, 6, 441-447 (1996).
19. S. J. London, A. K. Daly, J. B. Leathart, W. C. Navidi, C. C. Carpenter, and J. R. Idle, Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County, Carcinogenesis, 18, 1203-1214 (1997).
20. M. L. Bernal Ruiz, I. Johansson, P. Dalén, M.-L. Dahl, M. Ingelman-Sundberg, and L. Bertilsson, Gene duplication of CYP2D6 in a Spanish population, Pharmacogenetics (in press).
21. R. Fonne-Pfister and U. A. Meyer, Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism, Biochem. Pharmacol., 37, 3829-3835 (1988).
22. E. Lundqvist, I. Johansson, and M. Ingelman-Sundberg, Characterization of the CYP2D allelic locus containing duplicated functional CYP2D6 genes. Allele specific PCR analysis for determination of ultrarapid metabolizers, Gene (in press).
23. R. Lovlie, A. K. Daly, A. Molven, J. R. Idle, and V. M. Steen, Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett., 392, 30-34 (1996).
24. R. A. McLellan, M. Oscarson, A.-K. Alexandrie, J. Seidegård, D. A. P. Evans, A. Rannug, and M. Ingelman-Sundberg, Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene causing ultrarapid enzyme activity, Mol. Pharmacol., 52, 958-965 (1997).
25. P. Dalén, M.-L. Dahl, M. L. Bernal Ruiz, J. Nordin, and L. Bertilsson, 10-Hydroxylation of nortriptyline in Caucasians with 0, 1, 2, 3 and 13 functional CYP2D6 genes, Clin. Pharmacol. Ther., 63, 444-452 (1998).
26. R. F. Tyndale, K. P. Droll, and E. M. Sellers, Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence, Pharmacogenetics, 7, 375-379 (1997).
27. A. S. Aynacioglu, C. Sachse, J. Brockmöller, O. S. Kayaalp, A. Bozkurt, N. E. Basci, E. E. Tapanyigit, M. Nacak, and I. Roots, Allele frequencies of CYP2D6 and CYP2C19 in a Turkish population, in Microsomes, Drug Oxidation, and Clinical Pharmacology, a Satellite Symposium to the 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, Berlin, 1997 [Abstract].